Osimertinib in EGFR-Mutated Lung Cancer. Reply
N Engl J Med
.
2021 Feb 18;384(7):675-676.
doi: 10.1056/NEJMc2033951.
Authors
Roy S Herbst
1
,
Yi-Long Wu
2
,
Masahiro Tsuboi
3
Affiliations
1
Yale Cancer Center, New Haven, CT roy.herbst@yale.edu.
2
Guangdong Lung Cancer Institute, Guangzhou, China.
3
National Cancer Center Hospital East, Kashiwa, Japan.
PMID:
33596365
DOI:
10.1056/NEJMc2033951
No abstract available
Publication types
Letter
Comment
MeSH terms
Acrylamides*
Aniline Compounds
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Substances
Acrylamides
Aniline Compounds
osimertinib
EGFR protein, human
ErbB Receptors